Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course aminoglycosides added to beta-lactam therapy for adults with sepsis
NL-OMON53650Completed
- Sponsor
- University Medical Center Utrecht
- Start
- May 2022
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of cefuroxime, ceftriaxone, gentamicin and tobramycin in sepsis and bacterial disease (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: 30-day all-cause mortality. Started May 2022; status: completed.
02
Drugs
cefuroximeceftriaxonegentamicintobramycin
03
Conditions
sepsisbacterial disease
Beyond the preview
Go deeper on NL-OMON53650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53650.